Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Award

APCER Life Sciences Awarded ISO 27001:2013 Certification: Achieves Gold Standard for Information Security Management System


APCER Life Sciences, the preferred Pharmacovigilance services provider for Pharmaceutical and Biotech companies looking for compliance and adverse event reporting solutions across the drug life cycle, has been awarded the ISO/IEC 27001:2013 Certification. The globally recognized and accepted standard for Information Security Management System (ISMS) has been authorized by Intertek Certification Limited, UKAS (The United Kingdom Accreditation Service ? ISO accreditation body).

APCER's ?Patients First' approach enables it to deliver end-to-end drug safety, medical information, medical writing, regulatory affairs, quality assurance and risk management services to clients globally. ISO 27001:2013 vindicates APCER's prioritization of staying on top of the ever-changing data privacy landscape by investing in a robust security process that leverages the latest technology and best practices to help safeguard sensitive information.

APCER Life Sciences, a part of the APC Group, realizes value in achieving this important milestone. Gopal Menon, Vice Chairman, APC Group remarked, "Our company-wide approach to data protection ensures the highest possible standards of security and compliance for our customers. This certification is an endorsement of our commitment to information security. It plays an important role in assuring our customers that APCER Life Sciences takes necessary steps to keep their data confidential / secure, and accessible while maintaining its integrity."

"The ISO 27001:2013 Certification validates successful implementation of secure Information Security Practices which ensure compliance with global data protection regulations like EU-GDPR, UK-DPA, HIPAA etc. A risk-based proactive information security posture allows us to adapt and respond to the dynamic threat landscape and enhance customer and business partner confidence by ensuring business resilience," said Dr. Vineet Kacker, Managing Director and Global Technical Head, APCER Life Sciences.

This certification creates an external validation of APCER's internal processes including:

APCER (www.apcerls.com):

APCER brings medicinal / scientific expertise through its healthcare professionals & physicians to address full pharmacovigilance requirements globally, with five global offices and 800+ employees. APCER's clients benefit from its vast experience in regulatory submissions across 100+ countries and consultative approach towards audit /inspection readiness.


These press releases may also interest you

at 06:15
The "Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product, and Place with Executive & Consultant Guides and Customization. 2023 to 2027" report has been added to  ResearchAndMarkets.com's offering. Exciting technical...

at 06:10
Confo Therapeutics, a leader in the discovery of novel medicines targeting G-protein coupled receptors (GPCRs), announced today that it has been awarded a EUR 1.6 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The 2-year grant...

at 06:08
Aesthetic Management Partners LLC, a manufacturer of skin-based solutions and a provider of energy-based devices announces its collaboration with Croma (Croma-Pharma® GmbH), a global player in the minimally invasive aesthetics market and a leading...

at 06:05
The 2023 U.S. soybean field trials conducted by Texas Crop Science (TCS) demonstrated an average yield increase of 21% in soybean lines incorporating the TCS yield trait. This breakthrough in performance would generate approximately $121 per acre in...

at 06:05
3EO Health, a "Point of Life" diagnostics company focused on the development of high-performing low-cost molecular diagnostics, is excited to announce the next step in their quest to make molecular testing affordable. Today, the company has published...

at 06:05
Zura Bio Limited ("Zura Bio") a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights. The Company has also...



News published on and distributed by: